Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Breast Neoplasms 2Breast Diseases 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 215Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × figitumumab × Breast × Clear all
NCT00372996 2015-10-28

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Pfizer

Phase 2 Terminated
219 enrolled 11 charts
Breast

Breast Neoplasms

NCT00678626 2015-05-04

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Pfizer

Phase 2 Withdrawn
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡